source
- #ASCO26: Summit, Akeso drug reduces death by 34% in China lung cancer studyCHICAGO — The leading drug in biopharma's hottest immunotherapy race reduced the risk of death by 34% in previously untreated Chinese lung cancer patients, compared to standard immunotherapy plus c…Endpoints · 1mo ago↗ source
- STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drugMuch-awaited results at ASCO show that scientists have indeed found a way to drug a "greasy ball" involved in pancreatic cancer.STAT · 1mo ago↗ source
- STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancerA lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.